Kim Hyun Ju, Suh Chang-Ok
Department of Radiation Oncology, Gachon University Gil Hospital, Gachon University College of Medicine, Incheon, Korea.
Department of Radiation Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Brain Tumor Res Treat. 2023 Apr;11(2):79-85. doi: 10.14791/btrt.2022.0041.
Diffuse intrinsic pontine gliomas (DIPGs) account for 10%-20% of all central nervous system tumors in children and are the leading cause of death in children with brain tumors. Although many clinical trials have been conducted over the past decades, the survival outcome has remained unchanged. Over 90% of children die within 2 years of the diagnosis, and radiotherapy remains the standard treatment to date. To improve the prognosis, hyperfractionated and hypofractionated radiotherapy and/or addition of radiosensitizers have been investigated. However, none of the radiotherapy approaches have shown a survival benefit, and the overall survival of patients with DIPG is approximately 11 months. Here, we comprehensively review the management of DIPG with focus on radiotherapy.
弥漫性脑桥内在型胶质瘤(DIPG)占儿童所有中枢神经系统肿瘤的10%-20%,是儿童脑肿瘤的主要死因。尽管在过去几十年里进行了许多临床试验,但生存结果仍未改变。超过90%的儿童在确诊后2年内死亡,放疗至今仍是标准治疗方法。为了改善预后,人们研究了超分割和低分割放疗及/或添加放射增敏剂。然而,没有一种放疗方法显示出有生存获益,DIPG患者的总生存期约为11个月。在此,我们全面综述以放疗为重点的DIPG治疗。